The ELEVATUM study is designed to investigate how faricimab impacts DME in Black Americans. By enrolling, you'll contribute ...

When you have diabetes, it’s important to watch out for other serious health problems that can come along with it. Eye disease is a common condition that happens with diabetes. Blood sugar ...

Age-related macular degeneration (ARMD) is the leading cause of severe vision loss in the developed world for people over 55 ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline ...

Oculis has multiple late-stage programs and catalysts. Click here to find out why I think OCS stock looks attractive.

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...

a selective tyrosine kinase inhibitor formulated in proprietary bioerodible Durasert E™, for patients with diabetic macular edema (DME). DURAVYU 2.7mg demonstrated an early, sustained, and clinically ...

Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024Ophthalmology Innovation Summit XIV, November 23, 2024MELBOURNE, ...

Sunir J. Garg, MD, reflects on the recent American Academy of Ophthalmology meeting in Chicago and shares key insights on managing diabetic macular edema (DME). Dr Garg highlights new data showing ...